RecruitingNCT06867172

Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma

The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study


Sponsor

Carol Davila University of Medicine and Pharmacy

Enrollment

66 participants

Start Date

Jan 1, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS). The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Age 18 or older
  • Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam).

Exclusion Criteria7

  • No evidence of written informed consent
  • Patients with contraindications for endoscopy due to comorbidities
  • Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary)
  • Acute pancreatitis at baseline imaging
  • Pancreatic surgery at baseline imaging in our department
  • Splenectomy
  • Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women

Interventions

DIAGNOSTIC_TESTcomputerized tomography

Little is known about the prevalence of pancreatic steatosis in patients with pancreatic cystic lesions therefore this observational study aims to clarify the data.

DIAGNOSTIC_TESTEndosonography (EUS)

EUS can better evaluate all pancreatic cysts, therefore is mandatory in this observational study.


Locations(1)

Prof Dr Agrippa Ionescu; Clinical Emergency Hospital

Bucharest, Sector 1, Romania

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06867172


Related Trials